Business Context and Reporting Period
This Form 8-K was filed by Histogenics Corporation (trading symbol HSGX) on November 18, 2016. The filing addresses a regulatory notice received from The NASDAQ Stock Market LLC regarding the company's compliance with listing standards.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the Market Value of Listed Securities (MVLS), which fell below the required threshold of $50,000,000 for the last 30 consecutive business days.
Material Changes
- Listing Status: The company received a notice of non-compliance with NASDAQ Listing Rule 5450(b)(2)(A) due to insufficient MVLS.
- Trading Status: The notice has no immediate effect; common stock continues to trade on The NASDAQ Global Market under the symbol "HSGX."
Outlook, Risks, and Contingencies
Compliance Period: The company has been granted 180 calendar days, until May 17, 2017, to regain compliance.
Path to Compliance: To close the matter, the MVLS must close at $50,000,000 or more for a minimum of 10 consecutive business days on or before the deadline.
Delisting Risk: If compliance is not achieved by May 17, 2017, the company will be notified that its securities are subject to delisting.
Contingency Options: In the event of a delisting determination, the company may appeal to a NASDAQ Hearings Panel or apply to transfer its listing to The NASDAQ Capital Market, provided it meets those market's requirements.
Investor Verification Checklist
- Verify the current Market Value of Listed Securities (MVLS) to assess progress toward the $50,000,000 threshold.
- Monitor the stock price for 10 consecutive business days to determine if the compliance window is met.
- Review the company's capitalization strategy to understand how it plans to increase market value before the May 17, 2017 deadline.
- Check for any subsequent filings regarding an appeal or transfer to The NASDAQ Capital Market if the deadline is missed.